Randomized trial · people
Abaloparatide: fewer new vertebral fractures vs placebo in ACTIVE
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In a large phase 3 trial, abaloparatide cut new spine and nonvertebral fractures compared with placebo and caused high blood calcium less often than teriparatide.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 2463
- Published
- 2016
- Journal
- JAMA
What they tested
The team tested whether daily abaloparatide prevents new vertebral (spine bone) fractures better than placebo in postmenopausal women at risk of osteoporotic fractures, and how safe it is.
How the study was done
A phase 3, double-blind, randomized trial at 28 sites in 10 countries in 2463 postmenopausal women with low bone density, mean age 69. For 18 months they took a daily shot under the skin of placebo (a dummy shot), abaloparatide in the 80 μg arm, or teriparatide in the 20 μg arm, which was open-label, meaning everyone knew they were getting it.

What they found
New vertebral fractures seen on X-ray were less common in both active drug groups than with placebo. The estimated rate of nonvertebral fractures was lower with abaloparatide than with placebo. Bone mineral density (BMD) at the total hip, femoral neck and lumbar spine rose more with abaloparatide than with placebo. Hypercalcemia (high blood calcium) occurred in 3.4% of women on abaloparatide vs 6.4% on teriparatide (risk difference −2.96, 95% CI −5.12 to −0.87).
What it doesn’t show
The study included only postmenopausal women and lasted 18 months, and 1901 of the 2463 women completed it. The main test compared abaloparatide with placebo; the teriparatide arm was not blinded, so this was not a full head-to-head efficacy test against other osteoporosis drugs.
The paper
Miller et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016.
The compound
More studies on Abaloparatide
- Abaloparatide, teriparatide beat other drugs on spine BMD in menMeta-analysis · people · 2025
- Abaloparatide: larger hip BMD gains than teriparatide at 24 weeksMeta-analysis · people · 2023
- Abaloparatide raised hip BMD around a virtual hip stem in ACTIVERandomized trial · people · 2024
- Abaloparatide improved hip geometry vs placebo in ACTIVE-JRandomized trial · people · 2023
- Abaloparatide then alendronate: 84% lower vertebral fracture riskRandomized trial · people · 2018
- Abaloparatide: normal bone biopsies after up to 18 months in ACTIVERandomized trial · people · 2017
- Every study on Abaloparatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.